Anixa Biosciences (NASDAQ: ANIX) and the Moffitt Cancer Center, Anixa’s development partner, completed and validated the reformulation of the viral vector necessary for its CAR-T program.
The purpose of the reformulation is to increase the expression level of the Follicle Stimulating Hormone (FSH) on engineered, autologous T-cells. The new viral formulation is now being manufactured under GMP conditions and is expected to take about three months. Anixa and Moffitt remain on track to file IND application in 2020.
“Our laboratory completed the reformulation of the viral vector, and we have demonstrated its ability to increase the concentration of FSH on the surface of transformed human T-cells,” Dr. Jose Conejo-Garcia, chairman of the Department of Immunology at Moffitt, said in a statement.
“We expect the increased expression of FSH to provide better efficacy of our drug for ovarian cancer patients and look forward to taking this therapy into the clinic as soon as possible,” he added.
